{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:06Z","timestamp":1787013906118,"version":"build-2736575974"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adverse effects can compromise oral voriconazole treatment of pulmonary aspergillosis. Inhaled low\u2010dose voriconazole may be an alternative treatment. In this study, six patients inhaled 40 mg voriconazole b.i.d. for 2 days, and six patients ingested 400 and 200 mg orally b.i.d. on day one and two, respectively. Blood samples were collected after the first inhalation, and bronchial alveolar lavage fluids and blood samples were collected for measurements of voriconazole 12 hr after the last administration. The concentration of voriconazole in epithelial lining fluid (\n                    <jats:styled-content style=\"fixed-case\">ELF<\/jats:styled-content>\n                    ) was calculated by the urea dilution method. Voriconazole concentrations were detectable in plasma 15 min. after inhalation and declined at 30 and 60 min. Twelve hours after the last dose, median (95% CI) plasma voriconazole concentration was 8 (4\u201326) ng\/mL in the inhalation group and 1224 (535\u20132341) ng\/mL in the oral group (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). In\n                    <jats:styled-content style=\"fixed-case\">ELF<\/jats:styled-content>\n                    , median concentration was 190 (55\u2013318) ng\/mL and 8827 (4369\u201335172) ng\/mL, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). Median\n                    <jats:styled-content style=\"fixed-case\">ELF<\/jats:styled-content>\n                    \/plasma concentration ratio was 21 (6\u201363) in the inhalation group and 8 (3\u201320) in the oral group (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.2). In conclusion, voriconazole is rapidly absorbed into the systemic circulation after inhalation. There was a non\u2010significant trend towards a higher\n                    <jats:styled-content style=\"fixed-case\">ELF<\/jats:styled-content>\n                    \/plasma concentration ratio in the inhalation group compared to the oral group.\n                  <\/jats:p>","DOI":"10.1111\/bcpt.12820","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T14:16:44Z","timestamp":1497363404000},"page":"430-434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Voriconazole Concentrations in Plasma and Epithelial Lining Fluid after Inhalation and Oral Treatment"],"prefix":"10.1111","volume":"121","author":[{"given":"Charlotte U.","family":"Andersen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Aalborg and Aarhus University Hospital Aarhus C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Dahl","family":"S\u00f8nderskov","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases and Allergy Aarhus University Hospital Aarhus C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases and Allergy Aarhus University Hospital Aarhus C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Voldby","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases and Allergy Aarhus University Hospital Aarhus C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Cass","sequence":"additional","affiliation":[{"name":"Pulmocide London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ayrton","sequence":"additional","affiliation":[{"name":"Pulmocide London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[{"name":"Medical Department Vejle Hospital Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12834"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00163511"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203618"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00392945"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.12.014"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01042-09"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.10.014"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-13"}],"updated-by":[{"DOI":"10.1111\/bcpt.13177","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000}}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T08:46:36Z","timestamp":1695977196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/bcpt.12820"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12820","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"2017-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}